Non-hybrid glycemic control of type 1 diabetes ambulatory patients Control no-híbrido de glucemia ensayado en pacientes ambulatorios con Diabetes Tipo 1

GARELLI, FABRICIO; FUSHIMI, EMILIA; ROSALES, NICOLÁS; ARAMBARRI, DELFINA; SERAFINI, MARÍA CECILIA; DE BATTISTA, HERNÁN; GROSEMBACHER, LUIS A.; SÁNCHEZ-PEÑA, RICARDO S.

REVISTA IBEROAMERICANA DE AUTOMATICA E INFORMATICA INDUSTRIAL

COMITE ESPANOL AUTOMATICA CEA

Año: 2022 vol. 19 p. 318 - 329

1697-7912

In this work, we present the experience of our research group with the glucose regulation in people with Type 1 Diabetes (insulin-dependent), known as artificial pancreas. Our research group has carried out three clinical trials in Argentina, which were the first ones in Latin America. The first two studies took place in 2016 and 2017, both in the Hospital Italiano de Buenos Aires (HIBA) with five adult subjects and a duration of 36 hours. The second trial evaluated the performance of a novel closed-loop control algorithm (without meal insulin boluses), called ARG (Automatic Regulation of Glucose) and based on switched LQG control and a safety layer called SAFE (Safery Auxiliary Feedback Element), developed by researchers of our team. More recently and during COVID-19 pandemic, the first ambulatory trials took place, which were carried out in 2021 in a hotel with 5 subjects during 6 days. Additionally, for this third trial, the use of the artificial pancreas platform developed by the UNLP, called InsuMate, was incorporated. This platform connects a smartphone with the insulin pump and glucose monitor, houses the control algorithm, and allows the remote monitoring of multiple users. The results suggest that the ambulatory use of the ARG algorithm is feasible, safe and effective, compared to the usual treatment. In addition, the InsuMate platform was intuitive and easy to use for both healthcare staff and participants of the trial, achieving an over 95 % of time in closed-loop.